300573 兴齐眼药
交易中 07-24 09:39:51
资讯
新帖
简况
兴齐眼药：SQ-22031滴眼液为治疗用生物制品1类药物
证券之星 · 07-23 11:09
兴齐眼药：SQ-22031滴眼液为治疗用生物制品1类药物
兴齐眼药新注册《项目管理系统V1.0》等9个项目的软件著作权
证券之星 · 07-19
兴齐眼药新注册《项目管理系统V1.0》等9个项目的软件著作权
兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物
证券之星 · 07-11
兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物
兴齐眼药：公司2025年半年度报告预约披露时间为2025年8月28日
证券之星 · 07-08
兴齐眼药：公司2025年半年度报告预约披露时间为2025年8月28日
兴齐眼药：公司暂无拓展至五官科用药或宠物用药计划
证券之星 · 07-04
兴齐眼药：公司暂无拓展至五官科用药或宠物用药计划
兴齐眼药(300573.SZ)：SQ-22031滴眼液治疗神经营养性角膜炎Ⅱ期临床试验首例受试者入组
智通财经 · 06-27
兴齐眼药(300573.SZ)：SQ-22031滴眼液治疗神经营养性角膜炎Ⅱ期临床试验首例受试者入组
兴齐眼药：为保护全体股东权益，确保所有投资者平等获悉公司信息，公司会在定期报告中披露对应时点的股东人数
证券之星 · 06-16
兴齐眼药：为保护全体股东权益，确保所有投资者平等获悉公司信息，公司会在定期报告中披露对应时点的股东人数
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组
智通财经 · 06-16
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组
兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物
证券之星 · 05-30
兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物
兴齐眼药最新公告：SQ-22031滴眼液取得I期临床研究报告
证券之星 · 05-29
兴齐眼药最新公告：SQ-22031滴眼液取得I期临床研究报告
兴齐眼药最新公告：拟向特定对象发行股票 募资不超8.5亿元
证券之星 · 05-27
兴齐眼药最新公告：拟向特定对象发行股票 募资不超8.5亿元
兴齐眼药：2025年公司将围绕整体战略目标实现业务稳健增长
证券之星 · 05-26
兴齐眼药：2025年公司将围绕整体战略目标实现业务稳健增长
兴齐眼药：SQ-22031滴眼液为我公司研发的1类治疗用生物制品
证券之星 · 05-20
兴齐眼药：SQ-22031滴眼液为我公司研发的1类治疗用生物制品
兴齐眼药：公司上市以来一直通过聚焦主业等方式积极向市场传递公司投资价值
证券之星 · 05-19
兴齐眼药：公司上市以来一直通过聚焦主业等方式积极向市场传递公司投资价值
兴齐眼药(300573.SZ)2024年度拟每10股派10元转4股 5月22日除权除息
智通财经 · 05-14
兴齐眼药(300573.SZ)2024年度拟每10股派10元转4股 5月22日除权除息
兴齐眼药（300573）2025年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-29
兴齐眼药（300573）2025年一季报简析：营收净利润同比双双增长，盈利能力上升
图解兴齐眼药一季报：第一季度单季净利润同比增319.86%
证券之星 · 04-28
图解兴齐眼药一季报：第一季度单季净利润同比增319.86%
兴齐眼药(300573.SZ)发布一季度业绩，归母净利润1.46亿元，增长319.86%
智通财经 · 04-28
兴齐眼药(300573.SZ)发布一季度业绩，归母净利润1.46亿元，增长319.86%
兴齐眼药最新公告：一季度净利润同比增长319.86%
证券之星 · 04-28
兴齐眼药最新公告：一季度净利润同比增长319.86%
兴齐眼药(300573.SZ)发布2024年度业绩，归母净利润3.38亿元，增长40.84%
智通财经 · 04-21
兴齐眼药(300573.SZ)发布2024年度业绩，归母净利润3.38亿元，增长40.84%
加载更多
公司概况
公司名称：
沈阳兴齐眼药股份有限公司
所属行业：
医药制造业
上市日期：
2016-12-08
主营业务：
沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是凝胶剂、眼膏剂、滴眼剂、溶液剂、医疗服务、其他。2025年1月，公司荣获“国家级绿色工厂”称号。
发行价格：
5.16
{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":56.88,"timestamp":1753321191000,"preClose":56.4,"halted":0,"volume":1304114,"delay":0,"changeRate":0.0085,"floatShares":188000000,"shares":245000000,"eps":1.8309,"marketStatus":"交易中","change":0.48,"latestTime":"07-24 09:39:51","open":56.39,"high":56.89,"low":56.15,"amount":73887800,"amplitude":0.0131,"askPrice":56.9,"askSize":11,"bidPrice":56.87,"bidSize":30,"shortable":0,"etf":0,"ttmEps":1.8309,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1753327800000},"marketStatusCode":2,"adr":0,"adjPreClose":56.4,"symbolType":"stock","openAndCloseTimeList":[[1753320600000,1753327800000],[1753333200000,1753340400000]],"highLimit":62.04,"lowLimit":50.76,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":245348945,"isCdr":false,"pbRate":7.94,"roa":"--","peRate":31.066689,"roe":"8.75%","epsLYR":1.94,"committee":0.5,"marketValue":13955000000,"turnoverRate":0.0069,"status":0,"floatMarketCap":10719000000},"requestUrl":"/m/hq/s/300573","defaultTab":"news","newsList":[{"id":"2553121762","title":"兴齐眼药：SQ-22031滴眼液为治疗用生物制品1类药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2553121762","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553121762?lang=zh_cn&edition=full","pubTime":"2025-07-23 19:09","pubTimestamp":1753268948,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司创新药SQ-22031是否独家产品，主治什么症状，何时能推向市场？兴齐眼药回复：尊敬的投资者您好，公司在研产品SQ-22031滴眼液为治疗用生物制品1类药物，适应症为神经营养性角膜炎；干眼症。截至目前，经查询国家药品监督管理局网站，尚无同品种药品批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300033858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2552123412","title":"兴齐眼药新注册《项目管理系统V1.0》等9个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2552123412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552123412?lang=zh_cn&edition=full","pubTime":"2025-07-20 01:29","pubTimestamp":1752946149,"startTime":"0","endTime":"0","summary":"证券之星消息，近日兴齐眼药新注册了9个项目的软件著作权，包括《项目管理系统V1.0》、《药物警戒信息管理平台V1.0》、《兴齐药品注册申报应用平台V1.0》、《兴齐AI平台V1.0》、《会议管理系统V1.0》、《兴齐眼药微信公众平台内容管理系统V1.0》、《BI数据可视化平台V1.0》、《人力资源绩效管理系统V1.0》、《兴齐直通车通勤管理平台V1.0》等。今年以来兴齐眼药新注册软件著作权9个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000000362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2550608509","title":"兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2550608509","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550608509?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:12","pubTimestamp":1752196325,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药07月11日在投资者关系平台上答复投资者关心的问题。在公司的题材里，看见了兴齐眼药有创新药的概念，贵公司什么药品属于创新药？兴齐眼药回复：尊敬的投资者您好，公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物。公司上市以来一直通过稳健经营、切实履行信息披露义务、加强投资者沟通等方式，积极向市场传递公司投资价值并以持续稳定的现金分红积极回报投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100006405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","159992","BK1574","BK0239","06978","BK1161","BK0177"],"gpt_icon":0},{"id":"2549548565","title":"兴齐眼药：公司2025年半年度报告预约披露时间为2025年8月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2549548565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549548565?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:36","pubTimestamp":1751967366,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司25年中报什么公布？兴齐眼药回复：尊敬的投资者您好，公司2025年半年度报告预约披露时间为2025年8月28日。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800028740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2548363211","title":"兴齐眼药：公司暂无拓展至五官科用药或宠物用药计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2548363211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548363211?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:18","pubTimestamp":1751617098,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)07月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，公司目前聚焦眼科用药，新研发中心建成并投入使用后，研发是否会扩大到五官科用药或者皮肤科用药？是否会开展宠物用药进军宠物经济？兴齐眼药回复：尊敬的投资者您好，公司主营业务聚焦于眼科药物领域，未来将围绕整体战略目标，在眼科领域坚持研发创新，不断提升市场份额，暂无您提及的其他领域拓展计划，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400025121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2546947647","title":"兴齐眼药(300573.SZ)：SQ-22031滴眼液治疗神经营养性角膜炎Ⅱ期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2546947647","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546947647?lang=zh_cn&edition=full","pubTime":"2025-06-27 15:46","pubTimestamp":1751010379,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司研发的SQ-22031滴眼液于今日完成了“评估SQ-22031滴眼液治疗神经营养性角膜炎(NK)患者的随机、双盲、安慰剂、平行对照Ⅱ期临床试验”首例受试者入组，正式进入Ⅱ期临床试验。SQ-22031滴眼液完成首例受试者入组，正式进入Ⅱ期临床试验不会对公司近期业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1576","300573","BK0239","BK0177","BK1141","BK1583"],"gpt_icon":0},{"id":"2543211376","title":"兴齐眼药：为保护全体股东权益，确保所有投资者平等获悉公司信息，公司会在定期报告中披露对应时点的股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2543211376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543211376?lang=zh_cn&edition=full","pubTime":"2025-06-16 16:42","pubTimestamp":1750063346,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药06月16日在投资者关系平台上答复投资者关心的问题。请问把带有时间和姓名的股票交易软件持仓截图和身份证一并扫描发送至公司邮箱，可以获知 非定期报告相关时点的股东人数吗？盼你们具体，明确答复。顺祝健康，快乐 【比如截至到2025年6月10日贵公司的股东人数是多少？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600019993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2543298686","title":"兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2543298686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543298686?lang=zh_cn&edition=full","pubTime":"2025-06-16 16:14","pubTimestamp":1750061665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司研发的盐酸利多卡因眼用凝胶于今日完成了“评价盐酸利多卡因眼用凝胶用于眼表麻醉的有效性和安全性的随机、双盲、阳性药平行对照、安慰剂平行对照、多中心临床试验”的首例受试者入组，正式进入Ⅲ期临床试验。据悉，盐酸利多卡因是一种酰胺类局部麻醉药，被广泛用于浸润麻醉、硬膜外麻醉、表面麻醉及神经传导阻滞。盐酸利多卡因眼用凝胶可延长药物与眼表面接触时间，改善麻醉效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573","BK0177","BK1583","BK0239","BK1576","BK1141","03347"],"gpt_icon":0},{"id":"2539792229","title":"兴齐眼药：公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2539792229","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539792229?lang=zh_cn&edition=full","pubTime":"2025-05-30 19:15","pubTimestamp":1748603712,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)05月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，SQ-22031滴眼液是创新药还是仿制药？其作用是否对用眼习惯问题、长时间使用电子设备导致干眼症等眼部疾病有疗效？兴齐眼药回复：尊敬的投资者您好，公司在研产品SQ-22031滴眼液为治疗用生物制品1类创新药物，适应症为（1）神经营养性角膜炎；（2）干眼症。目前该产品的I期临床试验已取得临床研究报告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053000035009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK0177","BK1161","06978","300573","BK0239"],"gpt_icon":0},{"id":"2539252892","title":"兴齐眼药最新公告：SQ-22031滴眼液取得I期临床研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2539252892","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539252892?lang=zh_cn&edition=full","pubTime":"2025-05-29 19:09","pubTimestamp":1748516979,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)公告称，公司研发的SQ-22031滴眼液近日获得I期临床研究报告，该研究评估了SQ-22031滴眼液在健康受试者中的安全性、耐受性和药代动力学。试验结果显示本品安全性和耐受性良好，无严重不良事件发生。该药物为治疗用生物制品1类，适应症为神经营养性角膜炎，目前尚无同品种药品批准上市。本研究为后续临床试验开展提供了依据，但对公司近期业绩不会产生重大影响，后续项目审评审批进度及结果存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900031227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2538450701","title":"兴齐眼药最新公告：拟向特定对象发行股票 募资不超8.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538450701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538450701?lang=zh_cn&edition=full","pubTime":"2025-05-27 18:40","pubTimestamp":1748342429,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)公告称，公司拟向特定对象发行股票，募资不超过8.5亿元，用于研发中心建设项目和补充流动资金。本次发行的股票数量不超过本次发行前公司总股本的30%，即不超过73,604,683股。发行对象包括符合规定条件的证券投资基金管理公司、证券公司等，发行价格不低于定价基准日前二十个交易日公司股票交易均价的百分之八十。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052700030470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2538209261","title":"兴齐眼药：2025年公司将围绕整体战略目标实现业务稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2538209261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538209261?lang=zh_cn&edition=full","pubTime":"2025-05-26 15:35","pubTimestamp":1748244951,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药05月26日在投资者关系平台上答复投资者关心的问题。兴齐眼药回复：尊敬的投资者您好，2024年二季度至今，在面对激烈市场竞争环境下，公司经营展现出了良好的增长韧性与经营活力。2025年公司将围绕整体战略目标，在眼科领域坚持研发创新，采取广覆盖的全渠道营销模式，持续提升市场份额，实现业务稳健增长。同时，深化精细化管理，持续提升运营效率与盈利水平，力争以优异的业绩为股东带来稳定、长期的价值回报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052600014861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2536193036","title":"兴齐眼药：SQ-22031滴眼液为我公司研发的1类治疗用生物制品","url":"https://stock-news.laohu8.com/highlight/detail?id=2536193036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536193036?lang=zh_cn&edition=full","pubTime":"2025-05-20 18:45","pubTimestamp":1747737916,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有哪些在研的创新药项目？分别到什么阶段了？兴齐眼药回复：尊敬的投资者您好。SQ-22031滴眼液为我公司研发的1类治疗用生物制品，临床拟用于干眼症和神经营养性角膜炎。公司于2024年9月4日披露了《关于SQ-22031滴眼液Ⅰ期临床试验首例受试者入组的公告》，公司将根据信息披露相关规则，对研发进展进行公告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052000030735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2536684916","title":"兴齐眼药：公司上市以来一直通过聚焦主业等方式积极向市场传递公司投资价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2536684916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536684916?lang=zh_cn&edition=full","pubTime":"2025-05-19 20:48","pubTimestamp":1747658888,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药05月19日在投资者关系平台上答复投资者关心的问题。目前明显被低估，是否计划回购股份并注销。股票回购需根据公司资金安排并结合实际经营情况经决策后方可确定，未来如有回购相关计划，公司将依规进行公告 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051900032610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2535004334","title":"兴齐眼药(300573.SZ)2024年度拟每10股派10元转4股 5月22日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2535004334","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535004334?lang=zh_cn&edition=full","pubTime":"2025-05-14 17:51","pubTimestamp":1747216291,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司2024年年度拟向全体股东每10股派发现金红利10元(含税)，向全体股东每10股以资本公积金转增4股，本次权益分派股权登记日为2025年5月21日;除权除息日为2025年5月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2531712500","title":"兴齐眼药（300573）2025年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2531712500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531712500?lang=zh_cn&edition=full","pubTime":"2025-04-30 07:11","pubTimestamp":1745968302,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期兴齐眼药发布2025年一季报。截至本报告期末，公司营业总收入5.36亿元，同比上升53.24%，归母净利润1.46亿元，同比上升319.86%。本报告期兴齐眼药盈利能力上升，毛利率同比增幅5.33%，净利率同比增幅173.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000009328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2530471140","title":"图解兴齐眼药一季报：第一季度单季净利润同比增319.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530471140","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530471140?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:01","pubTimestamp":1745838105,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药2025年一季报显示，公司主营收入5.36亿元，同比上升53.24%；归母净利润1.46亿元，同比上升319.86%；扣非净利润1.36亿元，同比上升285.96%；负债率24.1%，财务费用95.13万元，毛利率80.16%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800029324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2530471512","title":"兴齐眼药(300573.SZ)发布一季度业绩，归母净利润1.46亿元，增长319.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530471512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530471512?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:00","pubTimestamp":1745838052,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布2025年第一季度报告，该公司营业收入为5.36亿元，同比增长53.24%。归属于上市公司股东的净利润为1.46亿元，同比增长319.86%。归属于上市公司股东的扣除非经常性损益的净利润为1.36亿元，同比增长285.96%。基本每股收益为0.83元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573"],"gpt_icon":0},{"id":"2530529421","title":"兴齐眼药最新公告：一季度净利润同比增长319.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530529421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530529421?lang=zh_cn&edition=full","pubTime":"2025-04-28 17:12","pubTimestamp":1745831552,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)发布2025年第一季度报告，公司实现营业收入5.36亿元，同比增长53.24%；归属于上市公司股东的净利润为1.46亿元，同比增长319.86%。营业收入增长主要系报告期内滴眼剂产品销售收入增长所致。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800026082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2529209378","title":"兴齐眼药(300573.SZ)发布2024年度业绩，归母净利润3.38亿元，增长40.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529209378","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529209378?lang=zh_cn&edition=full","pubTime":"2025-04-21 17:20","pubTimestamp":1745227244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布2024年年度报告，该公司营业收入为19.43亿元，同比增长32.42%。归属于上市公司股东的净利润为3.38亿元，同比增长40.84%。归属于上市公司股东的扣除非经常性损益的净利润为3.48亿元，同比增长44.54%。基本每股收益为1.94元。此外，拟向全体股东每10股派发现金红利10元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增4股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753321196154,"stockEarnings":[{"period":"1week","weight":0.0193},{"period":"1month","weight":0.1142},{"period":"3month","weight":0.1355},{"period":"6month","weight":0.1334},{"period":"1year","weight":-0.3924},{"period":"ytd","weight":0.1459}],"compareEarnings":[{"period":"1week","weight":0.0224},{"period":"1month","weight":0.0594},{"period":"3month","weight":0.0864},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.2288},{"period":"ytd","weight":0.0688}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42629人(较上一季度增加1.80%)","perCapita":"4420股","listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","registeredCapital":"24534万元","survey":" 沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是凝胶剂、眼膏剂、滴眼剂、溶液剂、医疗服务、其他。2025年1月，公司荣获“国家级绿色工厂”称号。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}